Core Insights - Bionano Genomics reported a decrease in total revenue for Q4 2025 and full year 2025, with total revenue of $8.0 million for Q4, down 3% from $8.2 million in Q4 2024, and $28.5 million for the full year, down 7% from $30.8 million in 2024 [4][21]. Financial Performance - Q4 2025 saw consumables and software revenues decrease by 1%, while instrument revenue slightly declined from $2.8 million in Q4 2024 to $2.7 million in Q4 2025 [4]. - The company sold 7,554 nanochannel array flowcells in Q4 2025, a 6% decrease from 8,058 flowcells sold in Q4 2024 [4]. - The installed base of OGM systems increased by 4% to 387 at the end of Q4 2025, up from 371 at the end of Q4 2024 [4]. - Gross margin improved to 43% in Q4 2025 from 42% in Q4 2024, with non-GAAP gross margin also at 43% [4]. - Operating expenses were reduced by 22% to $11.9 million in Q4 2025, and non-GAAP operating expenses decreased by 9% to $9.7 million [4]. Business Highlights - The company noted a 47% increase in the Clinical Lab Fee Schedule payment determination for the Category I CPT code for OGM use in hematologic malignancies, effective in 2026 [2][10]. - Bionano Symposium 2026 showcased advances in OGM, with nearly 40 presentations highlighting its applications in various fields, including hematologic malignancies and oncology research [10]. - The company reported 136 peer-reviewed publications in Q4 2025, indicating growing acceptance of OGM as a cytogenetic standard [10]. - Bionano initiated revenue guidance for Q1 2026 in the range of $6.5 to $6.7 million and for the full year 2026 in the range of $30 to $33 million [10]. Cash Position - As of December 31, 2025, Bionano ended the year with cash, cash equivalents, and available-for-sale securities totaling $29.6 million [4].

Core Viewpoint - Bionano Genomics is focusing on routine users of its optical genome mapping (OGM) systems and VIA™ software to drive revenue and gross profit, achieving a gross margin above 50% in Q2 2025, indicating a successful strategy shift [2][4]. Financial Results - Total revenue for Q2 2025 was $6.7 million, a decrease of 13% from $7.8 million in Q2 2024, primarily due to the discontinuation of clinical services [4]. - Consumables and software revenues increased by 16% compared to the prior year [4]. - Instrument revenue decreased from $2.3 million in Q2 2024 to $1.4 million in Q2 2025, reflecting the company's strategy to focus on routine users rather than new instrument placements [4]. - Adjusted for instrument sales and discontinued clinical services, combined revenue for consumables, software, and remaining services increased by 11% [4]. - The company sold 7,233 nanochannel array flowcells in Q2 2025, a 17% increase from 6,165 flowcells sold in Q2 2024 [4]. - Gross margin was 52% in Q2 2025, up from 33% in Q2 2024 [4][18]. - Operating expenses were reduced by 42% to $11.3 million, with non-GAAP operating expenses down by 53% to $8.8 million [4]. Business Highlights - The installed base of OGM systems increased by 4% to 378 at the end of Q2 2025 [4]. - The company achieved a record of 119 peer-reviewed publications, showcasing the growing utilization of OGM [4]. - Bionano announced upgrades to its VIA and Solve™ software, enhancing genomic data analysis capabilities [4]. - The American Medical Association established a second Category I CPT code for OGM use in cytogenomic genome-wide analysis [4]. 2025 Outlook - The company anticipates Q3 2025 revenue in the range of $6.7 to $7.2 million and full-year 2025 revenue between $26.0 to $30.0 million [11]. - Expectations for new OGM installations have been increased to 20 to 25 for the full year 2025 [11]. - The company ended Q2 2025 with cash and equivalents totaling $27.4 million, providing a cash runway into the first quarter of 2026 [4][11].